On Wednesday, Allegheny Technologies Incorporated (NYSE:ATI)’s shares inclined 0.03% to $32.11.
Allegheny Technologies Incorporated (ATI) declared that it is expanding its nickel-based superalloy powder capabilities to satisfy strong demand from the aerospace jet engine market and growing demand from the additive manufacturing industry, particularly for 3D printed parts used in the aerospace, medical, electrical energy, and oil and gas markets. The self-funded expansion, which is projected to cost about $70 million and take two years to complete, will be located at the ATI Specialty Materials business unit’s operations near Monroe, NC.
Allegheny Technologies Incorporated produces and sells specialty materials and components worldwide. The company operates through two segments, High Performance Materials and Components; and Flat-Rolled Products. The High Performance Materials and Components segment provides various high performance materials, counting titanium and titanium-based alloys; nickel-and cobalt-based alloys and superalloys; zirconium and related alloys, such as hafnium and niobium, advanced powder alloys, and other specialty materials, in long product forms of ingots, billets, bars, rods, wires, shapes and rectangles, and seamless tubes, plus precision forgings, castings, components, and machined parts.
CME Group Inc (NASDAQ:CME)’s shares dropped -1.19% to $93.66.
CME Group Inc (CME) the world’s leading and most diverse derivatives marketplace, and BarclayHedge recognized managed futures industry leaders at the fourth annual Managed Futures Pinnacle Awards last night. The ceremony featured live entertainment by Comedian Jay Mohr.
Cliff Asness, Managing and Founding Principal at AQR Capital Administration, won The Pinnacle Achievement Award. Prior to cofounding AQR Capital Administration, Asness was a managing director and director of quantitative research for the Asset Administration Division of Goldman, Sachs & Co. Cliff’s highly regarded research has offered value to investment professionals and has had an enormous impact on the financial services industry as a whole.
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals. The products comprise exchange-traded; and privately negotiated futures and options contracts and swaps. The company executes trades through its electronic trading platforms, open outcry, and privately negotiated transactions, in addition to provides hosting, connectivity, and customer support for electronic trading through its co-location services.
At the end of Wednesday’s trade, Finish Line Inc (NASDAQ:FINL)‘s shares surged 0.82% to $27.05.
Finish Line Inc (FINL) declared the following webcast:
What: First Quarter Fiscal 2016 Financial Results Conference Call
When: Friday, June 26, 2015 at 8:30 a.m. Eastern
The Finish Line, Inc., together with its auxiliaries, operates as a specialty retailer of athletic shoes, apparel, and accessories in the United States. It operates Finish Line stores that offer athletic shoes, in addition to apparel and accessories for men, women, and kids. The company also operates Running Specialty stores offering men’s and women’s performance running shoes, in addition to an assortment of performance apparel and accessories. In addition, The Finish Line, Inc. sells merchandise through its Websites finishline.com, boulderrunningcompany.com, and run.com, in addition to through m.finishline.com. As of April 16, 2015, it had about 1,030 Finish Line branded stores primarily in U.S. malls and shops inside Macy’s department stores; and 76 Running Specialty stores in 17 states and the District of Columbia.
Sequenom, Inc. (NASDAQ:SQNM), ended its Wednesday’s trading session with -3.11% loss, and closed at $3.12.
the development of innovative products and services, recently declared that its shareholders elected Catherine J. Mackey, Ph.D., as a new member of its Board of Directors, effective June 17, 2015. Dr. Mackey has also been designated to the Audit and Nominating and Corporate Governance committees of the Company’s Board of Directors.
Dr. Mackey is presently the Chief Executive Officer of CYPrus Therapeutics, Inc., a privately-held small molecule pharmaceutical development company. She is a Special Advisor to Fortis Advisors LLC, and serves on the Scientific Advisory Boards of FHOOSH, Inc. and Cypher Genomics. In addition, Dr. Mackey is a director and a member of the Finance and Audit & Compliance Committees of Rady Children’s Hospital and is past-chair of CONNECT. Dr. Mackey presently serves on the boards of privately-held companies Cour Pharmaceutical Development Company (Chair), Evolve Biosystems, Inc. and Viventia Bio, Inc.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women’s health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene fetal Rhesus D (RhD) LDT, a NIPT to determine the presence or absence of RhD factor by direct detection of the fetal RhD genotype in RhD negative mothers from a maternal blood sample; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
